English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/214432
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:

Title

Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer

AuthorsHellmann, Matthew D.; Paz-Ares, Luis CSIC; Bernabé Caro, Reyes; Zurawski, Bogdan; Kim, Sang-We; Carcereny Costa, Enric; Park, Keunchil; Alexandru, Aurelia; Lupinacci, Lorena; Mora Jiménez, Emmanuel de la; Sakai, Hiroshi; Albert, Istvan; Vergnenegre, Alain; Peters, Solange; Syrigos, Konstantinos; Barlesi, Fabrice; Reck, Martin; Borghaei, Hossein; Brahmer, Julie R.; O'Byrne, Kenneth J.; Geese, William J.; Bhagavatheeswaran, Prabhu; Rabindran, Sridhar K.; Kasinathan, Ravi S.; Nathan, Faith E.; Ramalingam, Suresh S.
Issue Date21-Nov-2019
PublisherMassachusetts Medical Society
CitationNew England Journal of Medicine 381: 2020-2031 (2019)
Abstract[Background] In an early-phase study involving patients with advanced non–small-cell lung cancer (NSCLC), the response rate was better with nivolumab plus ipilimumab than with nivolumab monotherapy, particularly among patients with tumors that expressed programmed death ligand 1 (PD-L1). Data are needed to assess the long-term benefit of nivolumab plus ipilimumab in patients with NSCLC.
[Methods] In this open-label, phase 3 trial, we randomly assigned patients with stage IV or recurrent NSCLC and a PD-L1 expression level of 1% or more in a 1:1:1 ratio to receive nivolumab plus ipilimumab, nivolumab alone, or chemotherapy. The patients who had a PD-L1 expression level of less than 1% were randomly assigned in a 1:1:1 ratio to receive nivolumab plus ipilimumab, nivolumab plus chemotherapy, or chemotherapy alone. All the patients had received no previous chemotherapy. The primary end point reported here was overall survival with nivolumab plus ipilimumab as compared with chemotherapy in patients with a PD-L1 expression level of 1% or more.
[Results] Among the patients with a PD-L1 expression level of 1% or more, the median duration of overall survival was 17.1 months (95% confidence interval [CI], 15.0 to 20.1) with nivolumab plus ipilimumab and 14.9 months (95% CI, 12.7 to 16.7) with chemotherapy (P=0.007), with 2-year overall survival rates of 40.0% and 32.8%, respectively. The median duration of response was 23.2 months with nivolumab plus ipilimumab and 6.2 months with chemotherapy. The overall survival benefit was also observed in patients with a PD-L1 expression level of less than 1%, with a median duration of 17.2 months (95% CI, 12.8 to 22.0) with nivolumab plus ipilimumab and 12.2 months (95% CI, 9.2 to 14.3) with chemotherapy. Among all the patients in the trial, the median duration of overall survival was 17.1 months (95% CI, 15.2 to 19.9) with nivolumab plus ipilimumab and 13.9 months (95% CI, 12.2 to 15.1) with chemotherapy. The percentage of patients with grade 3 or 4 treatment-related adverse events in the overall population was 32.8% with nivolumab plus ipilimumab and 36.0% with chemotherapy.
[Conclusions] First-line treatment with nivolumab plus ipilimumab resulted in a longer duration of overall survival than did chemotherapy in patients with NSCLC, independent of the PD-L1 expression level. No new safety concerns emerged with longer follow-up. (Funded by Bristol-Myers Squibb and Ono Pharmaceutical; CheckMate 227 ClinicalTrials.gov number, NCT02477826. opens in new tab.)
Publisher version (URL)http://dx.doi.org/10.1056/NEJMoa1910231
URIhttp://hdl.handle.net/10261/214432
DOIhttp://dx.doi.org/10.1056/NEJMoa1910231
Identifiersdoi: 10.1056/NEJMoa1910231
issn: 0028-4793
e-issn: 1533-4406
Appears in Collections:(IBIS) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.